R & D

R & D background

R & D pipeline

R & D pipeline

R & D pipeline

TISA-818

TISA-818‌, a novel chemical entity (NCE), is being developed for the treatment of acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), radiation-induced oral mucositis (SOM), and chronic obstructive pulmonary disease (COPD).

  1. ARDS‌: Phase II clinical trials are underway in China, with completion of patient enrollment anticipated by March 2025.
  2. COPD‌: Preparations are ongoing to submit applications for clinical trial authorization.
  3. IPF‌: Phase I clinical trials have been completed in Europe.
  4. SOM‌: A Phase Ib clinical trial has been initiated in China, expected to conclude in the second quarter of 2025.

Montelukast sodium

A highly potent, low-toxicity, and safe leukotriene receptor antagonist, has expanded its therapeutic scope through formulation innovation. It is now indicated for postoperative hemorrhoid care, burn wounds, chronic wounds, and radiation proctitis. The development and production rights for these four indications in mainland China have been licensed to ‌Shanghai Pharmaceutical (Group) Co., Ltd.‌. To date, Phase IIa clinical trials have been completed for ‌postoperative hemorrhoid management‌ and ‌radiation proctitis‌.

Intellectual Property

16 PCT patent applications for core innovations.

Number

First Submission Date

Application No

1

2017/07/05

PCT/CN2018/094441

2

2019/01/10

PCT/CN2020/071337

3

2021/08/06

PCT/CN2018/111247

4

2018/09/14

PCT/CN2019/105832

5

2017/07/05

PCT/CN2018/094441

6

2017/05/28

PCT/CN2019/088593

7

2017/07/05

PCT/CN2020/114828

8

2017/12/02

PCT/CN2020/133436

9

2017/03/17

PCT/CN2021/081361

10

2017/03/17

PCT/CN2021/081362

11

2017/12/02

PCT/CN2020/133438

12

2017/12/12

PCT/CN2020/133439

R & D pipeline

3 granted invention patents in China and 20 international granted invention patents.